CombiGene celebrates International Epilepsy Day
The International Epilepsy Day is held on the second Monday of February each year. There are 50 million people in the world living with epilepsy, of which 81,000 lives in Sweden. The purpose of International Epilepsy Day is for all the world’s epilepsy associations to jointly acknowledge and highlight the disease and its consequences. The day also includes coordinated information and education efforts to strengthen efforts worldwide for people with epilepsy.
International Epilepsy Day is a joint initiative between the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE) as well as their representation in 138 countries. With both national epilepsy federations and medical profession in close cooperation, alongside with cooperation with WHO and with IBE’s consultative status in the UN ECOSOC, International Epilepsy Day is the most prestigious epilepsy activity in the world.
For more information, see: https://internationalepilepsyday.org/
Source Svenska Epilepsiförbundet: https://bit.ly/3rtQgzl
CombiGenes Karin Agerman talks about the possibilities of gene therapy at the Swedish Epilepsy Association’s webinar on 8 February
CombiGene is a Swedish gene therapy company that develops a gene therapeutic treatment for epilepsy. This development project is in a late preclinical phase with the first human study scheduled for 2022. Karin Agerman, CombiGene’s Chief Research & Development Officer has been invited to speak under the heading Is gene therapy the future of treatment for epilepsy?
Information about the Swedish Epilepsy Association’s webinar
Link to Webinar: https://bit.ly/3oRtcJ0
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.